CD20-Targeted α-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma.
J Nucl Med.
2026 May 1;67(5):693-699. doi: 10.2967/jnumed.125.270515. PubMed PMID:
41644291; PubMed Central PMCID:
PMC13138093.
The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.
Blood Adv.
2026 Apr 14;10(7):2452-2469. doi: 10.1182/bloodadvances.2025017065. PubMed PMID:
41671449; PubMed Central PMCID:
PMC13083732.
Safety and equity in scaling minimally invasive surgery worldwide in 109 countries using cholecystectomy as a tracer procedure: a prospective cohort study.
Lancet Glob Health.
2026 Feb;14(2):e199-e212. doi: 10.1016/S2214-109X(25)00476-0. PubMed PMID:
41519150.
Intrathecal rituximab for the treatment of Epstein-Barr virus-associated encephalitis.
Front Immunol.
2025;16:1736017. doi: 10.3389/fimmu.2025.1736017. eCollection 2025. Review. PubMed PMID:
41459525; PubMed Central PMCID:
PMC12739377.
Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas.
Mol Cancer Ther.
2025 Dec 2;24(12):1928-1937. doi: 10.1158/1535-7163.MCT-24-0550. PubMed PMID:
40605797; PubMed Central PMCID:
PMC12396841.
The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.
bioRxiv.
2025 Apr 5;. doi: 10.1101/2025.04.04.645037. PubMed PMID:
40236126; PubMed Central PMCID:
PMC11996527.
Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
J Clin Oncol.
2025 Jan 10;43(2):201-213. doi: 10.1200/JCO.23.02018. Epub 2024 Sep 19. PubMed PMID:
39298738; PubMed Central PMCID:
PMC11709001.
(211)At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation.
J Nucl Med.
2024 Sep 3;65(9):1443-1449. doi: 10.2967/jnumed.124.267540. PubMed PMID:
39025648; PubMed Central PMCID:
PMC11372266.
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors.
Clin Cancer Res.
2024 Jan 17;30(2):274-282. doi: 10.1158/1078-0432.CCR-23-1200. PubMed PMID:
37939122; PubMed Central PMCID:
PMC10843688.
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Blood Adv.
2023 Sep 12;7(17):4950-4961. doi: 10.1182/bloodadvances.2023010392. PubMed PMID:
37339483; PubMed Central PMCID:
PMC10463192.
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
Eur J Haematol.
2023 Dec;111(6):863-871. doi: 10.1111/ejh.14089. Epub 2023 Sep 5. PubMed PMID:
37670560.
[(211)At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies.
Leuk Lymphoma.
2023 Jul-Aug;64(7):1335-1339. doi: 10.1080/10428194.2023.2210710. Epub 2023 May 11. PubMed PMID:
37170642; PubMed Central PMCID:
PMC10529842.
Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma.
EJNMMI Res.
2023 Apr 27;13(1):35. doi: 10.1186/s13550-023-00980-9. PubMed PMID:
37103671; PubMed Central PMCID:
PMC10140215.
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Leuk Lymphoma.
2023 May;64(5):927-937. doi: 10.1080/10428194.2023.2189803. Epub 2023 Mar 20. PubMed PMID:
36938892; PubMed Central PMCID:
PMC10357946.
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
Clin Infect Dis.
2023 Mar 4;76(5):926-929. doi: 10.1093/cid/ciac868. PubMed PMID:
36326680; PubMed Central PMCID:
PMC10226728.
Development of [(211)At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies.
Leukemia.
2022 Jun;36(6):1485-1491. doi: 10.1038/s41375-022-01580-7. Epub 2022 Apr 26. PubMed PMID:
35474099; PubMed Central PMCID:
PMC9177726.
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.
Blood Adv.
2022 Jan 11;6(1):37-45. doi: 10.1182/bloodadvances.2021005056. PubMed PMID:
34649272; PubMed Central PMCID:
PMC8753215.
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
Cancer.
2022 Apr 1;128(7):1411-1417. doi: 10.1002/cncr.34073. Epub 2021 Dec 21. PubMed PMID:
34931301.
Glypican-3-Targeted (227)Th α-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma.
J Nucl Med.
2022 Jul;63(7):1033-1038. doi: 10.2967/jnumed.121.262562. Epub 2021 Nov 12. PubMed PMID:
34772791; PubMed Central PMCID:
PMC9258570.
Glypican-3 targeted delivery of (89)Zr and (90)Y as a theranostic radionuclide platform for hepatocellular carcinoma.
Sci Rep.
2021 Feb 12;11(1):3731. doi: 10.1038/s41598-021-82172-w. PubMed PMID:
33580090; PubMed Central PMCID:
PMC7881163.
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and (90)Y-DOTA.
Mol Cancer Ther.
2020 Dec;19(12):2575-2584. doi: 10.1158/1535-7163.MCT-20-0306. Epub 2020 Oct 20. PubMed PMID:
33082277; PubMed Central PMCID:
PMC7718432.
(90)Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma.
Bone Marrow Transplant.
2021 Jan;56(1):202-209. doi: 10.1038/s41409-020-01000-3. Epub 2020 Jul 24. PubMed PMID:
32710011; PubMed Central PMCID:
PMC8328580.
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies.
J Nucl Med.
2020 Sep;61(9):1300-1306. doi: 10.2967/jnumed.119.234443. Epub 2020 Mar 13. PubMed PMID:
32169919; PubMed Central PMCID:
PMC7456175.
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.
Blood.
2019 Oct 10;134(15):1247-1256. doi: 10.1182/blood.2019001250. PubMed PMID:
31395601; PubMed Central PMCID:
PMC6788008.
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.
Leukemia.
2020 Feb;34(2):635-639. doi: 10.1038/s41375-019-0586-6. Epub 2019 Oct 4. PubMed PMID:
31586148.
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.
Haematologica.
2020 Jun;105(6):1731-1737. doi: 10.3324/haematol.2019.229492. Epub 2019 Oct 3. PubMed PMID:
31582553; PubMed Central PMCID:
PMC7271581.
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Haematologica.
2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. PubMed PMID:
30409798; PubMed Central PMCID:
PMC6442971.
cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies.
PLoS One.
2018;13(10):e0205135. doi: 10.1371/journal.pone.0205135. eCollection 2018. PubMed PMID:
30335787; PubMed Central PMCID:
PMC6193629.
Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS.
American Society of Hematology; 2017 December; Atlanta, GA. Blood 2017, 130:2048.: American Society of Hematology; c2017.
Novel Bispecific Antibody Targeting CD45 and 90Y-DOTA Is Effective Therapy for Acute Myeloid Leukemia in Preclinical Murine Models.
American Society of Hematology; 2017 December; Atlanta, GA. Blood 2017, 130:1355: American Society of Hematology; c2017.
Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities.
Eur J Haematol.
2018 Feb;100(2):140-146. doi: 10.1111/ejh.12991. Epub 2017 Nov 23. PubMed PMID:
29105850.
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Blood.
2018 Feb 8;131(6):611-620. doi: 10.1182/blood-2017-09-807610. Epub 2017 Nov 20. PubMed PMID:
29158362; PubMed Central PMCID:
PMC5805491.
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
Cancer Res.
2017 Jul 15;77(14):3885-3893. doi: 10.1158/0008-5472.CAN-17-0082. Epub 2017 May 31. PubMed PMID:
28566329; PubMed Central PMCID:
PMC5560265.
Effectiveness of environmental control measures to decrease the risk of invasive aspergillosis in acute leukaemia patients during hospital building work.
J Hosp Infect.
2017 Aug;96(4):336-341. doi: 10.1016/j.jhin.2017.04.022. Epub 2017 May 5. PubMed PMID:
28545828.
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.
Cancer Res.
2016 Nov 15;76(22):6669-6679. doi: 10.1158/0008-5472.CAN-16-0571. Epub 2016 Sep 2. PubMed PMID:
27590740; PubMed Central PMCID:
PMC5290195.
Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia.
Endocrinol Nutr.
2016 Nov;63(9):466-474. doi: 10.1016/j.endonu.2016.05.011. Epub 2016 Aug 30. PubMed PMID:
27595241.
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.
Blood.
2016 Jan 21;127(3):352-9. doi: 10.1182/blood-2014-12-617019. Epub 2015 Nov 17. PubMed PMID:
26576864; PubMed Central PMCID:
PMC4722286.
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.
Br J Haematol.
2015 Dec;171(5):788-97. doi: 10.1111/bjh.13773. Epub 2015 Oct 12. PubMed PMID:
26455717; PubMed Central PMCID:
PMC4715476.
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.
Ann Oncol.
2015 Nov;26(11):2323-8. doi: 10.1093/annonc/mdv364. Epub 2015 Sep 7. PubMed PMID:
26347113; PubMed Central PMCID:
PMC4621031.
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Biol Blood Marrow Transplant.
2016 Feb;22(2):380-385. doi: 10.1016/j.bbmt.2015.08.035. Epub 2015 Sep 5. PubMed PMID:
26348890; PubMed Central PMCID:
PMC4716882.
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.
Med Phys.
2015 Jul;42(7):4094-105. doi: 10.1118/1.4921997. PubMed PMID:
26133610; PubMed Central PMCID:
PMC4464071.
Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia.
Cost Eff Resour Alloc.
2015;13:6. doi: 10.1186/s12962-015-0032-1. eCollection 2015. PubMed PMID:
25878563; PubMed Central PMCID:
PMC4397735.
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
PLoS One.
2015;10(3):e0120561. doi: 10.1371/journal.pone.0120561. eCollection 2015. PubMed PMID:
25785845; PubMed Central PMCID:
PMC4364776.
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.
Blood.
2015 Mar 26;125(13):2111-9. doi: 10.1182/blood-2014-11-612770. Epub 2015 Jan 27. PubMed PMID:
25628467; PubMed Central PMCID:
PMC4375108.
Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
PLoS One.
2014;9(12):e113601. doi: 10.1371/journal.pone.0113601. eCollection 2014. PubMed PMID:
25460570; PubMed Central PMCID:
PMC4252056.
In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.
Cancer Res.
2014 Oct 15;74(20):5846-54. doi: 10.1158/0008-5472.CAN-14-0764. Epub 2014 Sep 26. PubMed PMID:
25261237; PubMed Central PMCID:
PMC4199906.
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.
BMC Infect Dis.
2014 Mar 28;14:172. doi: 10.1186/1471-2334-14-172. PubMed PMID:
24679135; PubMed Central PMCID:
PMC3994250.
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
Cancer Res.
2014 Feb 15;74(4):1179-89. doi: 10.1158/0008-5472.CAN-13-1589. Epub 2013 Dec 26. PubMed PMID:
24371230; PubMed Central PMCID:
PMC3970848.
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.
Blood.
2013 May 2;121(18):3759-67. doi: 10.1182/blood-2012-11-467035. Epub 2013 Mar 7. PubMed PMID:
23471305; PubMed Central PMCID:
PMC3643772.
Unfavorable, complex, and monosomal karyotypes: the most challenging forms of acute myeloid leukemia.
Oncology (Williston Park).
2012 Aug;26(8):706-12. PubMed PMID:
22957403.
What would you like to do?